Uncontrolled arterial hypertension in the mirror of ethiopathogenetic, diagnostic and clinical aspects of the disease

7th International Congress of Cardionephrology KARNEF (2025) [pp. 289-306]

AUTHOR(S) / AUTOR(I): Goran Koraćević , Slađana Mićić, Milovan Stojanović

Download Full Pdf   

DOI: 10.46793/KARNEF25.301K

ABSTRACT / SAŽETAK:

The term uncontrolled hypertension (UH) is commonly applied to all patients with hypertension (HTA) who do not achieve their target blood pressure (BP) for various reasons, which may include pseudoresistance or resistant HTA. Resistant HTA is defined as a BP reading exceeding 140/90 mmHg in the doctor’s office in patients who are on three or more antihypertensive medications, including diuretics, at optimal or maximally tolerated doses. Pseudoresistant HTA encompasses improper BP measurement techniques, white-coat effect, drug-induced HTA, secondary HTA, and incorrectness in antihypertensive management, whether due to suboptimal medication or nonadherence to treatment by patients. To define true resistant HTA, it is necessary to confirA adherence to treatment and eliminate potential secondary causes of HTA; otherwise, resistant HTN is merely apparent and termed as pseudoresistant HTA. For patients experiencing resistant HTA, the fourth-line treatment generally involves the use of a mineralocorticoid receptor antagonist (MRA), primarily spironolactone, followed by a beta blocker as the fifth option. The term refractory HTA refers to an ‘extreme phenotype’ of HTA, which is defined by the inability to control BP even when utilizing a regimen of five or more antihypertensive agents, including two of them being a long-acting thiazide-like diuretic and MRA. Acutely elevated BP also represent uncontrolled HTA, with guidelines recognizing at least two forms: moderately severe and extremely severe HTA crisis. The treatment approaches for these two categories differ significantly. We proposed a third category that addresses intermediate risk, which seems to be a logical extension of existing classifications.

 KEYWORDS / KLJUČNE REČI:

uncontrolled hypertension, resistant hypertension, pseudoresistant hypertension, refractory hypertension, hypertensive crises

REFERENCES / LITERATURA:

  • Vemulapalli S, Ard J, Bakris GL, Bhatt DL, et al. Proceedings from Duke resistant hypertension think tank. Am Heart J 2014; 167(6): 775-788.e1. doi: 10.1016/j.ahj.2014.02.008.
  • De Rosa ML Resistant hypertension: Definition, evaluation, and new therapeutic approaches to treatment. Dis Disord 2017; 1: 1-8. doi: 10.15761/JDD.1000101
  • Dudenbostel T, Siddiqui M, Gharpure N, Calhoun DA. Refractory versus resistant hypertension: Novel distinctive phenotypes. J Nat Sci 2017; 3(9): e430. 
  • Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874-2071. doi: 10.1097/HJH.0000000000003480.
  • Gifford RW Jr, Tarazi RC. Resistant hypertension: diagnosis and management. Ann Intern Med. 1978 May;88(5):661-5. doi: 10.7326/0003-4819-88-5-661.
  • Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension 2020, 75, 1334–1357. doi: 10.1161/HYPERTENSIONA-HA.120.15026.
  • Kreutz R, Brunström M, Burnier M, et al. 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension. Eur J Intern Med 2024; 126: 1-15. doi: 10.1016/j.ejim.2024.05.033. 
  • Williams B, Mancia G, Spiering W, et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39(33): 3021-3104. doi: 10.1093/eurheartj/ehy339. 
  • Koraćević G. Beta blokatori su heterogena klasa – farmakološki kriterijumi za izbor. Galenika Medical Journal 2022; 1(3): 106-110.
  • Koracevic G, Micic S, Stojanovic M, et al. Compelling Indications Should be Listed for Individual Beta-Blockers (Due to Diversity), Not for the Whole Class. Curr Vasc Pharmacol 2021; 19(4): 343-346. doi: 10.2174/1570161118666200518113833. 
  • Koraćević G, Stojanović M, Kostić T, et al. Contraindications Differ Widely Among Beta Blockers and Ought to be Cited for an Individual Drug, Not for the Entire Class. Curr Pharm Des 2021; 27(40): 4125-4132. doi: 10.2174/1381612827666210716162130. 
  • Osler W: The principles and practice of medicine. New York: D. Appleton, 1892
  • Bansal N, Artinian NT, Bakris G, et al.; American Heart Association Council on the Kidney in Cardiovascular Disease; Council on Cardiovascular and Stroke Nursing; and Council on Epidemiology and Prevention. Hypertension in Patients Treated With In-Center Maintenance Hemodialysis: Current Evidence and Future Opportunities: A Scientific Statement From the American Heart Association. Hypertension 2023; 80(6): e112-e122. doi: 10.1161/HYP.0000000000000230. 
  • Charles L, Triscott J, Dobbs B. Secondary Hypertension: Discovering the Underlying Cause. Am Fam Physician. 2017;96(7):453-461.
  • McEvoy JW, McCarthy CP, Bruno RM, et al-; ESC Scientific Document Group. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 2024; 45(38): 3912-4018. doi: 10.1093/eurheartj/ehae178.
  • Koracevic G, Stojkovic M, Lovic D, et al. Should Cushing’s Syndrome be Considered as a Disease with High Cardiovascular Risk in Relevant Guidelines? Curr Vasc Pharmacol 2020; 18(1): 12-24. doi: 10.2174/1570161116666181005122339.
  • Koracevic GP, Stojanovic MS, Stojanovic SS, et al. Rationale to search for masked hypertension in severe Cushing’s disease. Minerva Med 2023; 114(1): 91-94. doi: 10.23736/S0026-4806.19.06327-4.
  • Koracevic G, Mićić S, Stojanović M, et al. High likelihood for atrial fibrillation in Cushing’s syndrome. Eur Rev Med Pharmacol Sci 2020; 24(3): 1391-1397. doi: 10.26355/eurrev_202002_20196.
  • Koracevic G, Zdravkovic M, Koracevic M, et al. A SUGGESTION FOR PROACTIVE CARDI-OLOGIC APPROACH TO CUSHING’S SYNDROME OR DISEASE Facta Universitatis Series: Medicine and Biology 2023; 24(22): 51-55. doi: 10.22190/FUMB210130007K
  • Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart 2019; 105(2): 98-105. doi: 10.1136/heartjnl-2018-313599. 
  • Roberie DR, Elliott WJ. What is the prevalence of resistant hypertension in the United States? Curr Opin Cardiol 2012; 27(4): 386-391. doi: 10.1097/HCO.0b013e328353ad6e.
  • Koracevic G, Micic S, Stojanovic M, et al. A Need for Improvement in the Definition of Resistant Arterial Hypertension. Medicina (Kaunas) 2023; 59(4): 803. doi: 10.3390/medicina59040803. 
  • Acelajado MC, Hughes ZH, Oparil S, et al. Treatment of Resistant and Refractory Hypertension. Circ Res. 2019; 124(7): 1061-1070. doi: 10.1161/CIRCRESAHA.118.312156.
  • Tian Z, Vollmer Barbosa C, Lang H, et al. Efficacy of pharmacological and interventional treatment for resistant hypertension: a network meta-analysis. Cardiovasc Res 2024; 120(1): 108-119. doi: 10.1093/cvr/cvad165. 
  • Filippone EJ, Naccarelli GV, Foy AJ. Controversies in Hypertension V: Resistant and Refractory Hypertension. Am J Med 2024; 137(1): 12-22. doi: 10.1016/j.amjmed.2023.09.015
  • Mehta ND, Battle SJ, DiPette DJ. Cardiac structure and function in resistant hypertension: The beneficial role of blood pressure control. J Clin Hypertens (Greenwich) 2023; 25(5): 426-428. doi: 10.1111/jch.14626
  • Shalaeva EV, Messerli FH. What is resistant arterial hypertension? Blood Press 2023; 32(1): 2185457. doi: 10.1080/08037051.2023.2185457. 
  • Chobanian AV, Bakris GL, Black HR, et al.; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289(19): 2560-2572. doi: 10.1001/jama.289.19.2560. 
  • Lewington S, Clarke R, Qizilbash N, et al.; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360(9349): 1903-1913. doi: 10.1016/s0140-6736(02)11911-8.
  • Grassi G, Cifkova R, Laurent S, et al. Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE study. Eur Heart J 2011; 32(2): 218-225. doi: 10.1093/eurheartj/ehq394. 
  • Teo K, Chow CK, Vaz M, et al.; PURE Investigators-Writing Group. The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. Am Heart J 2009; 158(1): 1-7.e1 doi: 10.1016/j.ahj.2009.04.019.
  • Koracevic GP. Aortic dissection and aneurysm are hypertensive target organ damages and should be listed in the guidelines. Am J Emerg Med 2019; 37(2): 365-366. doi: 10.1016/j.ajem.2018.06.047.
  • Blood Pressure Lowering Treatment Trialists’ Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet 2021; 397(10285): 1625-1636. doi: 10.1016/S0140-6736(21)00590-0.
  • Bacan G, Ribeiro-Silva A, Oliveira VAS, et al. Refractory Hypertension: a Narrative Systematic Review with Emphasis on Prognosis. Curr Hypertens Rep 2022; 24(4): 95-106. doi: 10.1007/s11906-022-01165-w. 
  • Siddiqui M, Judd EK, Dudenbostel T, et al. Antihypertensive Medication Adherence and Confirmation of True Refractory Hypertension. Hypertension 2020; 75(2): 510-515. doi: 10.1161/HYPERTENSI-ONAHA.119.14137. 
  • Filippone EJ, Naccarelli GV, Foy AJ. Controversies in Hypertension V: Resistant and Refractory Hypertension. Am J Med 2024; 137(1): 12-22. doi: 10.1016/j.amjmed.2023.09.015.
  • Matanes F, Khan MB, Siddiqui M, et al. An Update on Refractory Hypertension. Curr Hypertens Rep 2022; 24(7): 225-234. doi: 10.1007/s11906-022-01185-6. 
  • Koracevic G, Stojanovic M, Zdravkovic M, et al. Proposal of a Modified Classification of Hypertensive Crises: Urgency, Impending Emergency, and Emergency. Curr Vasc Pharmacol 2024; 22(3):180-186. doi: 10.2174/0115701611270174231204110557.